Your Joint OptionsFind my next step

Medically reviewed by Charles A. DeCook, MD ·

← All options
Learn about the evidence

Glucosamine / chondroitin

Popular supplements. Not new cartilage.

01

What could it help with?

Glucosamine and chondroitin are popular, but evidence for meaningful knee or hip OA benefit is inconsistent. ACR recommends against their use for these joints. [1][2]

02

Who might it suit?

For: An evidence check before buying a supplement.

Not for: A cartilage-regrowth claim or a replacement for core care.

03

Limits and important cautions

A finding for a pharmaceutical-grade preparation or for hand OA does not validate an over-the-counter knee supplement. Interactions and product quality still matter.

What happens, how long, and what could it cost?
What happens
Review the precise ingredients and doses with a clinician or pharmacist, including interactions.
When might I notice a change?
A reliable personal timeline cannot be predicted from the evidence reviewed here. Agree on a review date before starting.
How long might benefit last?
Benefit and durability depend on the exact intervention and population. The evidence section below explains what is known.
Repeat treatment
Set a review point and avoid indefinite purchases without meaningful benefit.
Activity and recovery
Discuss interactions and whether the product should be paused around surgery.
Ask for a complete estimate
The exact formulation, ongoing purchases, and any monitoring.

Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.

Compare expectations side by side ↗

THE EVIDENCE IN CONTEXT

Inconsistent benefit; not routine OA care

Read the 2 selected references
  1. ACR/Arthritis Foundation: OA management ↗Clinical guideline · 2020

    2019 guideline, published in 2020. Recommendations vary by joint; it predates many newer trials.

  2. AAOS: nonsurgical knee OA care ↗Clinical guideline · 2021

    Knee-specific guidance; evidence strength varies by treatment. It should not be applied automatically to hip disease.

Editorial synthesis · reviewed September 19, 2026. These are selected decision-relevant references, not an exhaustive systematic review or a new formal evidence grade. FDA status and coverage are assessed separately.

FDA status

Supplements · no disease-treatment approval

Supplements are not FDA-approved OA drugs.

Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.
What do professional guidelines say?

AAOS: Reports limited, inconsistent evidence of possible benefit for some supplements; not strong support.

ACR: Strongly against glucosamine and against chondroitin for knee or hip OA.

Will Medicare cover it?

Supplements are not covered OA drugs.

How we interpret changing evidence